ArcherDX, Inc. Closes $35 Million Series A Financing

BOULDER, CO—ArcherDX, Inc., the leader in NGS-based gene fusion detection tests, announced today that it has closed a $35 million Series A Preferred financing, which was co-led by Boulder Ventures, Ltd. and PBM Capital Group, LLC. Longwood Fund and Peierls Foundation also participated in the Series A financing as new investors. Kyle Lefkoff of Boulder Ventures has joined the ArcherDX, Inc. Board of Directors.

The capital comes after a year of record growth for the company and penetration into liquid biopsy, immune sequencing, and companion diagnostic (CDx) markets. The company will use the funding to support the rapid commercial growth of its targeted sequencing tests, including expanding its domestic salesforce, increasing its international commercial operations, scaling its oncology-focused CDx co-development program and continuing to invest in its in vitro diagnostic (IVD) pipeline.

Dr. Jason Myers, CEO and Co-founder of ArcherDX, said in a statement, “We’ve been very successful in developing the technology, establishing scalable processes and driving rapid revenue growth. This round of funding, and the addition of Kyle to our board, will help us to execute on our mission of providing the best molecular pathology tools both in research and clinical settings on a global scale.”

Kyle Lefkoff of Boulder Ventures said in a statement, “The rapid adoption of ArcherDX’s workflow by leading cancer centers and pharma companies has been impressive. We look forward to supporting Jason and the ArcherDX, Inc. team in their efforts to improve the lives of patients through improved genetic targeting of new therapies.”

You are now leaving Links to sites outside of ArcherDX are provided as a resource to the viewer. ArcherDX accepts no responsibility for the content of linked sites. 

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.